Edwards Lifesciences (EW) TAVR Franchise Captured More Share Than Previously Thought - Cowen

February 18, 2020 3:25 PM EST Send to a Friend
Cowen analyst Joshua Jennings reiterated an Outperform rating and $275.00 price target on Edwards Lifesciences (NYSE: EW), noting the TAVR ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login